cy·no·sure

(ˈsī-nə-ˌshu̇r) noun

1) constellation Ursa Minor, also Polaris or North star;

2) one that serves to direct/guide

David R. Compton, PhD, DABT

David Compton is a highly accomplished and visionary Toxicology Executive, with multifaceted expertise in pre-clinical drug development, gene therapy, toxicology, neuropharmacology, and Good Laboratory Practice (GLP) regulations.

Possesses over 35 years of combined academic, CRO, and pharmaceutical experience, with a focus on therapeutic areas such as anti-nausea, immunology, asthma, oncology, allergy, osteoarthritis, and gene therapy (AAV / lentiviral vectors). A proven record of success in leading drug development activities for gene therapies and abuse liability assessment of small molecules. Leverages exemplary leadership, organizational, and communication skills to drive innovation and achieve exceptional outcomes.

About David See experience

Areas of Expertise

AAV Gene Therapy

With experience developing gene therapy programs, nonclinical development programs and IND-enabling GLP toxicity studies we have worked extensively in AAV Gene Therapy. The U.S. Food and Drug Administration (FDA) granted the Regenerative Medicine Advanced Therapy (RMAT) designation to one of our programs based on positive 6-month efficacy data from the Phase I/II clinical trial.

Learn more

Abuse Liability Assessment

We have over 35 years of experience in abuse liability assessment working for small biotech companies as well as large pharmaceutical companies. This has included an academic focus on drug abuse research and education, Safety Pharmacology, and serving as a subject matter expert (SME) on abuse liability assessment advising all company drug development programs advancing to the NDA or BLA stage from 2005 to 2020.

Learn more